Elikya Therapeutics

Elikya is pleased to showcase our ground-breaking new technology focusing on toxic payloads for Antibody Drug Conjugates (ADCs) at the prestigious pitch studio of Gustave Roussy during VivaTech 2024 in Paris (May 23rd 2024 @ 5:15pm CET). Join us as we unveil our latest innovation that is set to revolutionize the industry! Elikya Therapeutics, a Landmark BioVentures AG company, and spinoff from the Gustave Roussy and Université Paris-Saclay is focused on the development of next Generation of ADCs using its First-in-Class toxic payload, with a unique mode of able to address tumor and its microenvironment in parallel, and with a long-standing memory immune response. Elikya's unique approach focuses also on the development of Precision Conjugates: considering that new ADCs shall be designed on the comprehensive mechanistic properties of the payload (payload centric design). @BPI Quest for health , Gustave Roussy Transfert. SATT Paris-Saclay #Elikya #Innovation #ADCs #VivaTech

Looking forward to pitching Elikya Therapeutics at VivaTech next week in Paris, France Gustave Roussy, Gustave Roussy Transfert #ADC, #VivaTech

🚀 Exciting findings in the realm of ADCs and in the key role of payloads to develop effective treatments against cancer!  The latest study conducted by Chen et al. dives deep into the effectiveness of alternative payload strategies in treating lung cancer, shedding light on a potentially game-changing approach. Traditionally, much emphasis has been placed on novel targeting in the development of antibody-drug conjugates (ADCs). However, the research suggests that simply swapping out payloads could offer a higher probability of success compared to pursuing novel targeting. In this investigation involving 79 lung cancer patients, with a majority being HER2-positive, they found that maintaining the same payload while switching antibody formats yielded marginal benefits, with an overall response rate (ORR) of approximately 5.3%. However, the story took a significant turn when they explored the impact of swapping payloads. The ORR skyrocketed to an impressive 22.6% with this approach. What's more intriguing is the observation that in patients with advanced disease progression, a switch to a different payload led to remarkable outcomes. A staggering 41.2% ORR was noted in these patients, with some experiencing durable responses lasting more than 6 months. A compelling case study further illustrates this point, comparing trastuzumab deruxtecan (T-Dxd) with disitamab vedotin (RC48). The difference in progression-free survival 2 (PFS2) between the two treatments was striking, with T-Dxd demonstrating a PFS2 of 5.37 months compared to 3.30 months for RC48. Furthermore, the overall survival (OS) with T-Dxd extended to an impressive 50.6 months, in stark contrast to 20.2 months with RC48. These findings underscore the potential of alternative payload strategies in enhancing the efficacy of cancer therapies, particularly in patients with advanced disease. By focusing on payloads selection, we could pave the way for more effective treatment options and improved patient outcomes. Elikya Therapeutics, a Landmark BioVentures company, is focused on the development of next Generation of ADCs using its First-in-Class toxic payload, with a unique mode of able to address tumor and its microenvironment in parallel, and with a long-standing memory immune response. Elikya's unique approach focuses also on the development of Precision Conjugates: considering that new ADCs shall be designed on the comprehensive mechanistic properties of the payload (payload centric design). #ADCs #toxicpayloads #Precisionsconjugates. #CancerResearch #Innovation #TherapeuticAdvancements